• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Renovorx Inc (NQ: RNXT )

    1.370 -0.090 (-6.16%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 29,072
    Open 1.400
    Bid (Size) 1.370 (1)
    Ask (Size) 1.430 (8)
    Prev. Close 1.460
    Today's Range 1.360 - 1.450
    52wk Range 0.5306 - 3.290
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
    From RenovoRx, Inc.
    Via Business Wire
    RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024
    RNXT stock results show that RenovoRx beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -30.81%
    -30.81%
    1 Month
    +15.13%
    +15.13%
    3 Month
    -0.72%
    -0.72%
    6 Month
    +128.33%
    +128.33%
    1 Year
    -36.28%
    -36.28%

    More News

    Read More
    RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
    From RenovoRx , Inc.
    Via Business Wire
    RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
    Via InvestorPlace
    RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
    From RenovoRx, Inc.
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    RenovoRx Announces $11.1 Million at Market Private Placement
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx Highlights Key Leadership Promotions
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx CEO Issues Letter to Shareholders
    From RenovoRx, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    RenovoRx Closes $6.1 Million Private Placement
    From RenovoRx, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Clinical Trials at Major University; New Application Targeting Tumors with an IP Portfolio of 9 Patents Issued, 9 Pending for Cancer Treatments Partnered with Imugene: RenovoRx (NASDAQ: RNXT)
    Via Get News
    Topics Intellectual Property
    Exposures Intellectual Property
    RenovoRx (NASDAQ: RNXT) Elevates IP Portfolio with New Application and Advances Cancer Treatments in Phase 3 Clinical Trials
    Via Get News
    Topics Intellectual Property
    Exposures Intellectual Property
    RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
    From RenovoRx, Inc.
    Via Business Wire
    RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
    From RenovoRx, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.